Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Viking Therapeutics (VKTX) shares experienced a sharp decline, halving in value, following Phase 2 clinical data for its oral obesity drug, primarily due to investor concerns over a 28% discontinuation rate linked to tolerability issues. However, BTIG analyst Justin Zelin argues the market reaction is "overdone," asserting the drug's efficacy is competitive with leading candidates from Eli Lilly and Novo Nordisk. Zelin attributes the high dropout rate to an aggressive initial dosing strategy, which he expects will be refined in Phase 3, and highlights that most side effects were mild and transient, suggesting strong long-term commercial viability and presenting a significant buying opportunity for investors willing to look past immediate headline risks.

Analysis

Viking Therapeutics (VKTX) shares experienced a severe sell-off, halving in value, after its Phase 2 oral obesity drug data revealed a 28% discontinuation rate, sparking investor fears over tolerability and competitive viability against Eli Lilly and Novo Nordisk. However, a contrarian view from BTIG analyst Justin Zelin posits that this market reaction is 'overdone'. The analyst attributes the high dropout rate to an 'unusually aggressive' dose escalation in the trial, a factor not expected to persist in a refined Phase 3 protocol. Supporting this, 99% of gastrointestinal side effects were reported as mild-to-moderate and resolved within three weeks. Critically, the drug demonstrated competitive efficacy, with mid-dose cohorts showing favorable results versus rivals, and compelling data on a lower maintenance dose supported long-term commercial potential. Zelin's reiterated 'buy' rating and $125 price objective, implying 450% upside, underscores a belief that the market is misinterpreting manageable, front-loaded side effects and underappreciating the drug's class-leading potential.

Key Decisions for Investors

• Investors with a high risk tolerance could view the sharp sell-off as a compelling entry point, capitalizing on the significant disconnect between the market's headline reaction and the analyst's positive fundamental assessment.
• It is critical to monitor for Viking's forthcoming Phase 3 trial design, as a more conservative dosing strategy would serve as a major de-risking event and validate the thesis that tolerability issues are manageable.
• While the upside potential is substantial, any position should be sized appropriately, acknowledging the binary risk inherent in clinical-stage biotech and the intense competitive pressure from established market leaders.
• Consider the analyst's price target of $125 and the lowest Street target of $29 as valuation goalposts that frame the current risk/reward profile, suggesting a potential floor even in a more conservative scenario.